Table 2 Top five prognosis-related canonical pathways in Group 3
From: Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma
Database | Name of gene set (GSEA) | Exploratory dataset (n = 74) | Validation dataset (n = 33) | 1000 bootstrap datasets (n = 107) | Representative core genes** | ||
|---|---|---|---|---|---|---|---|
HR* | p-value | HR* | p-value | % of p-value < 0.05 | |||
PID | Notch-mediated HES/HEY network | 2.71 | 0.0001 | 2.21 | 0.087 | 98.8 | MYOD1,KDM1A,GAA,MYB,CTBP1 |
Class I PI3K signaling events mediated by Akt | 2.08 | 0.0044 | 2.40 | 0.021 | 97.1 | YWHAZ,PRKDC,CDKN1B | |
p53 pathway | 2.15 | 0.0052 | 1.79 | 0.071 | 92.8 | DYRK2,RPL23,PPM1D,RPL11 | |
C-MYC pathway | 1.69 | 0.0087 | 2.26 | 0.040 | 89.4 | RUVBL1,ACTL6A,RUVBL2 | |
Regulation of retinoblastoma protein | 2.01 | 0.0094 | 2.23 | 0.146 | 89.0 | MYOD1,E2F3,CDKN1B,CDK4,CTBP1 | |
KEGG | Tyrosine metabolism | 3.40 | 0.0002 | 5.22 | 0.000 | 100.0 | COMT,MIF,GOT2 |
Melanoma | 4.86 | 0.0001 | 4.64 | 0.048 | 99.5 | FGF2,E2F3,CDK4 | |
Bladder cancer | 2.57 | 0.0040 | 5.73 | 0.020 | 97.2 | MYC,E2F3,CDK4 | |
Proteasome | 1.94 | 0.0014 | 1.94 | 0.031 | 96.9 | PSMB3,PSMC3,PSMB1,PSMC5,PSMD3, PSMA5,PSMB7,PSMA4,PSMD12,PSMA6,PSMD14 | |
Galactose metabolism | 2.13 | 0.0037 | 2.50 | 0.009 | 95.2 | GLA,GAA,PGM2 | |
BIOCARTA | IL-2 Receptor Beta Chain in T cell Activation | 3.60 | 0.0002 | 6.49 | 0.009 | 99.9 | PPIA,STAT5B,MYC |
Proteasome Complex | 1.82 | 0.0041 | 1.67 | 0.038 | 95.5 | PSMB3,PSMC3,PSMB1,RPN1,PSMA5,PSMB7, PSMA4,PSMD12,PSMA6,PSMD14 | |
Influence of Ras and Rho proteins on G1 to S | 1.87 | 0.0216 | 4.20 | 0.012 | 92.1 | CDKN1B,CDK4 | |
How Progesterone Initiates Oocyte Membrane | 1.99 | 0.0183 | 3.66 | 0.041 | 86.4 | ARPC3 | |
CDK Regulation of DNA Replication | 1.31 | 0.0418 | 1.42 | 0.173 | 74.6 | MCM2,MCM5,ORC6,MCM4,CDT1,CDKN1B | |